49 Review of potential geographical disparities in access to anti-fibrotic medication and clinic-based specialist palliative care for patients with idiopathic pulmonary fibrosis

Background Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease of unknown origin (NICE, 2013). Disease-modifying anti-fibrotics are restricted to patients who meet specific criteria and are prescribed by regional IPF centres (NICE, 2016; NICE, 2018). Patients should be offered best supportive care from diagnosis (NICE, 2013). In January 2016 specialist palliative care (SPC) support was embedded in a regional IPF clinic. Initial service review (Kavanagh, 2017) suggested potential geographical disparities in access to both anti fibrotics and clinic-based SPC. Aim To repeat the 2016 review to assess whether geographical disparities have changed over time. Methods The sex, age and postcode of all patients with known IPF prescribed anti-fibrotics or seen by clinic-based SPC between January 2016 and April 2019 were collected retrospectively and geographically plotted. Chi squared goodness of fit was used to calculate statistical significance. Results 398 patients were started on anti-fibrotics (male:female 330:68, mean age 74.7). Geographical plotting shows significant variation by region (P Discussion Geographical distribution of patients seen by clinic-based SPC appears to have changed little since 2016, with clear centralisation to Newcastle-Gateshead. Speculatively, reasons for this could include travel distances and local palliative care provision. Geographical disparity in antifibrotic prescription is more difficult to account for and requires further investigation. References National Institute for Health Care and Excellence (NICE). (2013) Idiopathic Pulmonary Fibrosis in Adults (CG163) [online]. https://www.nice.org.uk/guidance/cg163. Accessed 04/07/2019. National Institute for Health Care and Excellence (NICE). (2016) Nintedanib for Treating Idiopathic Pulmonary Fibrosis (Technology Appraisal Guidance TA379) [online]. https://www.nice.org.uk/guidance/ta379. Accessed 04/07/2019. National Institute for Health Care and Excellence (NICE). (2018) Pirfenidone for Treating Idiopathic Pulmonary Fibrosis (Technology Appraisal Guidance TA504) [online]. https://www.nice.org.uk/guidance/ta504/chapter/1-Recommendations. Accessed 04/07/2019. Kavanagh E, et al. Integration of specialist palliative care into a tertiary non-malignant service: evaluation of potential geographical disparity. BMJ Supportive & Palliative Care 2017;7(Suppl 1):A33–A34.